Radionanomedicine: Widened perspectives of molecular theragnosis

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 4, 2015, Pages 795-810

  Lee, Dong Soo ^a,b   Im, Hyung Jun ^b   Lee, Yun Sang ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Biodistribution; Encapsulation; Nanomedicine; Radiolabeling; Theragnosis

Indexed keywords

ENCAPSULATION; NANOSTRUCTURED MATERIALS; TRACE ANALYSIS;

BIODISTRIBUTIONS; CLINICAL TRANSLATION; ENCAPSULATION METHODS; IMMUNE RESPONSE; MULTIFUNCTIONALITY; RADIOLABELING; THERAGNOSIS; TRACER TECHNOLOGY;

MEDICAL NANOTECHNOLOGY;

NANOMATERIAL; RADIOACTIVE MATERIAL;

BIODEGRADATION; EXCRETION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IN VIVO STUDY; ISOTOPE LABELING; ISOTOPE TRACING; MOLECULAR DIAGNOSIS; MOLECULAR IMAGING; MOLECULAR THERAGNOSIS; MOLECULAR THERAPY; NANOENCAPSULATION; NANOMEDICINE; NUCLEAR MEDICINE; PHYSIOLOGY; RADIATION DOSE DISTRIBUTION; RADIONANOMEDICINE; REVIEW; SURFACE PROPERTY; PROCEDURES; THERANOSTIC NANOMEDICINE; TRENDS;

HUMANS; THERANOSTIC NANOMEDICINE;

EID: 84929302587     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.12.010     Document Type: Review

References (170)

1. Kagan V.E., Bayir H., Shvedova A.A. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine 2005, 1(4):313-316.
2. Garnett M.C., Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med (Lond) 2006, 56(5):307-311.
3. Maurer-Jones M.A., Bantz K.C., Love S.A., Marquis B.J., Haynes C.L. Toxicity of therapeutic nanoparticles. Nanomedicine (Lond) 2009, 4(2):219-241.
4. Donaldson K., Aitken R., Tran L., Stone V., Duffin R., Forrest G. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006, 92(1):5-22.
5. Sun G., Xu J., Hagooly A., Rossin R., Li Z., Moore D.A., et al. Strategies for optimized radiolabeling of nanoparticles for in vivo pet imaging. Adv Mater 2007, 19(20):3157-3162.
6. Sun M., Hoffman D., Sundaresan G., Yang L., Lamichhane N., Zweit J. Synthesis and characterization of intrinsically radiolabeled quantum dots for bimodal detection. Am J Nucl Med Mol Imaging 2012, 2(2):122-135.
7. Yang L., Sundaresan G., Sun M., Jose P., Hoffman D., McDonagh P.R., et al. Intrinsically radiolabeled multifunctional cerium oxide nanoparticles for in vivo studies. J Mat Chem B 2013, 1(10):1421-1431.
8. 64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. J Am Chem Soc 2010, 132(43):15351-15358.
9. 64Cu-doped iron oxide nanoparticles. ACS Nano 2012, 6(4):3461-3467.
10. Zhao Y., Sultan D., Detering L., Cho S., Sun G., Pierce R., et al. Copper-64-alloyed gold nanoparticles for cancer imaging: improved radiolabel stability and diagnostic accuracy. Angew Chem Int Ed Engl 2014, 53(1):156-159.
11. Lin X., Xie J., Niu G., Zhang F., Gao H., Yang M., et al. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett 2011, 11(2):814-819.
12. Liu T.W., MacDonald T.D., Shi J., Wilson B.C., Zheng G. Intrinsically copper-64-labeled organic nanoparticles as radiotracers. Angew Chem Int Ed Engl 2012, 51(52):13128-13131.
13. Katti K.V., Kannan R., Katti K., Kattumori V., Pandrapraganda R., Rahing V., et al. Hybrid gold nanoparticles in molecular imaging and radiotherapy. Czechoslov J Phys 2006, 56(1):D23-D34.
14. 198Au radioactive composite nanodevices and their use for nanobrachytherapy. Nanomedicine (Lond) 2008, 4(1):57-69.
15. 198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomedicine (Lond) 2010, 6(2):201-209.
16. 198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A 2012, 109(31):12426-12431.
17. Zhou C., Hao G., Thomas P., Liu J., Yu M., Sun S., et al. Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics. Angew Chem Int Ed Engl 2012, 51(40):10118-10122.
18. Wang Y., Liu Y., Luehmann H., Xia X., Wan D., Cutler C., et al. Radioluminescent gold nanocages with controlled radioactivity for real-time in vivo imaging. Nano Lett 2013, 13(2):581-585.
19. Yang Y., Sun Y., Cao T., Peng J., Liu Y., Wu Y., et al. Hydrothermal synthesis of NaLuF4:153Sm, Yb, Tm nanoparticles and their application in dual-modality upconversion luminescence and SPECT bioimaging. Biomaterials 2013, 34(3):774-783.
20. Sun Y., Zhu X., Peng J., Li F. Core-shell lanthanide upconversion nanophosphors as four-modal probes for tumor angiogenesis imaging. ACS Nano 2013, 7(12):11290-11300.
21. 111In-labeled Fe3O4 nanoparticles. Chem Commun (Camb) 2014, 50(17):2170-2172.
22. Sun Y., Yu M., Liang S., Zhang Y., Li C., Mou T., et al. Fluorine-18 labeled rare-earth nanoparticles for positron emission tomography (PET) imaging of sentinel lymph node. Biomaterials 2011, 32(11):2999-3007.
23. 18F-Labeled magnetic-upconversion nanophosphors via rare-Earth cation-assisted ligand assembly. ACS Nano 2011, 5(4):3146-3157.
24. Chen F., Ellison P.A., Lewis C.M., Hong H., Zhang Y., Shi S., et al. Chelator-free synthesis of a dual-modality PET/MRI agent. Angew Chem Int Ed Engl 2013, 52(50):13319-13323.
25. Chakravarty R., Valdovinos H.F., Chen F., Lewis C.M., Ellison P.A., Luo H., et al. Intrinsically germanium-69-labeled iron oxide nanoparticles: synthesis and in-vivo dual-modality PET/MR imaging. Adv Mater 2014, 26(30):5119-5123.
26. Morales-Avila E., Ferro-Flores G., Ocampo-Garcia B.E., De Leon-Rodriguez L.M., Santos-Cuevas C.L., Garcia-Becerra R., et al. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor alpha(v)beta(3) expression. Bioconjug Chem 2011, 22(5):913-922.
27. 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging. J Biomed Nanotechnol 2010, 6(4):375-384.
28. 99mTc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection. Nucl Med Biol 2011, 38(1):1-11.
29. Zhang G., Yang Z., Lu W., Zhang R., Huang Q., Tian M., et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 2009, 30(10):1928-1936.
30. 99mTc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging. Bioconjug Chem 2011, 22(3):455-465.
31. Cai W., Chen K., Li Z.B., Gambhir S.S., Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007, 48(11):1862-1870.
32. Chen K., Conti P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010, 62(11):1005-1022.
33. Xie H., Diagaradjane P., Deorukhkar A.A., Goins B., Bao A., Phillips W.T., et al. Integrin alphavbeta3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine 2011, 6:259-269.
34. Lee H.Y., Li Z., Chen K., Hsu A.R., Xu C., Xie J., et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008, 49(8):1371-1379.
35. 64Cu-labeled magnetic nanoparticles for multimodal imaging. Bioconjug Chem 2008, 19(7):1496-1504.
36. 64Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem 2010, 21(4):715-722.
37. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2(1):47-52.
38. 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials 2011, 32(9):2334-2341.
39. 99mTc-C(60)(OH)(x) and its biodistribution studies. Nucl Med Biol 2002, 29(6):707-710.
40. Guo J., Zhang X., Li Q., Li W. Biodistribution of functionalized multiwall carbon nanotubes in mice. Nucl Med Biol 2007, 34(5):579-583.
41. Singh R., Pantarotto D., Lacerda L., Pastorin G., Klumpp C., Prato M., et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A 2006, 103(9):3357-3362.
42. McDevitt M.R., Chattopadhyay D., Kappel B.J., Jaggi J.S., Schiffman S.R., Antczak C., et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007, 48(7):1180-1189.
43. Zhang R., Lu W., Wen X., Huang M., Zhou M., Liang D., et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med 2011, 52(6):958-964.
44. Park J.C., Yu M.K., An G.I., Park S.I., Oh J., Kim H.J., et al. Facile preparation of a hybrid nanoprobe for triple-modality optical/PET/MR imaging. Small 2010, 6(24):2863-2868.
45. Lee J., Lee T.S., Ryu J., Hong S., Kang M., Im K., et al. RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J Nucl Med 2013, 54(1):96-103.
46. Cao J., Wang Y., Yu J., Xia J., Zhang C., Yin D., et al. Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy. J Magn Magn Mater 2004, 277(1-2):165-174.
47. Liang S., Wang Y., Yu J., Zhang C., Xia J., Yin D. Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy. J Mater Sci Mater Med 2007, 18(12):2297-2302.
48. 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 2007, 27(4B):2217-2225.
49. 177lu-labeled gold nanoparticles-RGD internalized in breast cancer cells. J Mex Chem Soc 2013, 57:212-219.
50. Lee Y.K., Jeong J.M., Hoigebazar L., Yang B.Y., Lee Y.S., Lee B.C., et al. Nanoparticles modified by encapsulation of ligands with a long alkyl chain to affect multispecific and multimodal imaging. J Nucl Med 2012, 53(9):1462-1470.
51. Hwang D.W., Ko H.Y., Lee J.H., Kang H., Ryu S.H., Song I.C., et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010, 51(1):98-105.
52. Goel S., Chen F., Ehlerding E.B., Cai W. Intrinsically radiolabeled nanoparticles: an emerging paradigm. Small 2014, 10(19):3825-3830.
53. Xing Y., Zhao J., Conti P.S., Chen K. Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics 2014, 4(3):290-306.
54. Enrique Morales-Avila G.F.-F., Ocampo-García Blanca E., Ramírez Flor de María Radiolabeled nanoparticles for molecular imaging. InTech 2012, B. Schaller (Ed.).
55. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010, 110(5):2858-2902.
56. Lee Y.S. Radiopharmaceutical chemistry. Handbook of nuclear medicine and molecular imaging 2012, 21-51. World Scientific Publishing Co. Pte. Ltd., NJ, USA. E.E.L.D. Kim, U. Tateishi, R. Baum (Eds.).
57. 68Ga-radiopharmaceutical development. Theranostics 2013, 4(1):47-80.
58. 64Cu. Biomed Res Int 2014, 786463.
59. Anderson C.J., Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 2009, 24(4):379-393.
60. 89Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules 2013, 18(6):6469-6490.
61. Kam B.L.R., Teunissen J.J.M., Krenning E.P., de Herder W.W., Khan S., van Vliet E.I., et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012, 39(1):103-112.
62. 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2012, 39(3):501-511.
63. Goffredo V., Paradiso A., Ranieri G., Gadaleta C.D. Yttrium-90 in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Crit Rev Oncol Hematol 2011, 80(3):393-410.
64. 188Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm 2003, 18(5):707-717.
65. Hong H., Zhang Y., Sun J., Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 2009, 4(5):399-413.
66. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160(2):117-134.
67. Seregni E.M.A., Chiesa C., Scaramellini G., Massimino M., Bombardieri E. Radioiodine therapy of differentiated thyroid cancer. Nuclear medicine therapy 2013, 133-153. Springer, NY, USA. C.G.S. Aktolun (Ed.).
68. Parker C., Nilsson S., Heinrich D., Helle S.I., O'Sullivan J.M., Fosså S.D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369(3):213-223.
69. Yong K.T., Law W.C., Hu R., Ye L., Liu L., Swihart M.T., et al. Nanotoxicity assessment of quantum dots: from cellular to primate studies. Chem Soc Rev 2013, 42(3):1236-1250.
70. Boisselier E., Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009, 38(6):1759-1782.
71. Xie G., Sun J., Zhong G., Shi L., Zhang D. Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Arch Toxicol 2010, 84(3):183-190.
72. Khlebtsov N., Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011, 40(3):1647-1671.
73. Chen Y.S., Hung Y.C., Liau I., Huang G.S. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res Lett 2009, 4(8):858-864.
74. de Barros A.B., Tsourkas A., Saboury B., Cardoso V.N., Alavi A. Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res 2012, 2(1):39.
75. Nam J., Won N., Bang J., Jin H., Park J., Jung S., et al. Surface engineering of inorganic nanoparticles for imaging and therapy. Adv Drug Deliv Rev 2013, 65(5):622-648.
76. 68Ga-labeled affibody molecules. J Nucl Med 2010, 51(6):892-897.
77. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.-N.T., LaVan D.A., Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004, 64(21):7668-7672.
78. Saw P.E., Kim S., I-h Lee, Park J., Yu M., Lee J., et al. Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J Mat Chem B 2013, 1(37):4723-4726.
79. Ruigrok V.J., Levisson M., Eppink M.H., Smidt H., van der Oost J. Alternative affinity tools: more attractive than antibodies?. Biochem J 2011, 436(1):1-13.
80. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat Rev Cancer 2012, 12(4):278-287.
81. Kim H.K., Kim S., Park J.J., Jeong J.M., Mok Y.J., Choi Y.H. Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer. Ann Thorac Surg 2011, 91(5):1517-1522.
82. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-hodgkin's lymphoma. J Clin Oncol 2002, 20(10):2453-2463.
83. 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005, 46(Suppl. 1):128S-140S.
84. 89Zr and IRdye 800cw. Mol Pharm 2012, 9(8):2339-2349.
85. Rezaeipoor R., John R., Adie S.G., Chaney E.J., Marjanovic M., Oldenburg A.L., et al. Fc-directed antibody conjugation of magnetic nanoparticles for enhanced molecular targeting. J Innov Opt Health Sci 2009, 2(4):387-396.
86. Kumar S., Aaron J., Sokolov K. Directional conjugation of antibodies to nanoparticles for synthesis of multiplexed optical contrast agents with both delivery and targeting moieties. Nat Protoc 2008, 3(2):314-320.
87. Cardoso M.M., Peca I.N., Roque A.C. Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem 2012, 19(19):3103-3127.
88. Wang H., Liu Y.L., Yang Y.H., Deng T., Shen G.L., Yu R.Q. A protein A-based orientation-controlled immobilization strategy for antibodies using nanometer-sized gold particles and plasma-polymerized film. Anal Biochem 2004, 324(2):219-226.
89. Mazzucchelli S., Colombo M., De Palma C., Salvade A., Verderio P., Coghi M.D., et al. Single-domain protein a-engineered magnetic nanoparticles: toward a universal strategy to site-specific labeling of antibodies for targeted detection of tumor cells. ACS Nano 2010, 4(10):5693-5702.
90. Makaraviciute A., Ramanaviciene A. Site-directed antibody immobilization techniques for immunosensors. Biosens Bioelectron 2013, 50:460-471.
91. Salehi M., Schneider L., Strobel P., Marx A., Packeisen J., Schlucker S. Two-color SERS microscopy for protein co-localization in prostate tissue with primary antibody-protein A/G-gold nanocluster conjugates. Nanoscale 2014, 6(4):2361-2367.
92. Dubertret B., Skourides P., Norris D.J., Noireaux V., Brivanlou A.H., Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002, 298(5599):1759-1762.
93. Fan H., Yang K., Boye D.M., Sigmon T., Malloy K.J., Xu H., et al. Self-assembly of ordered, robust, three-dimensional gold nanocrystal/silica arrays. Science 2004, 304(5670):567-571.
94. Fan H., Leve E.W., Scullin C., Gabaldon J., Tallant D., Bunge S., et al. Surfactant-assisted synthesis of water-soluble and biocompatible semiconductor quantum dot micelles. Nano Lett 2005, 5(4):645-648.
95. Wu H., Zhu H., Zhuang J., Yang S., Liu C., Cao Y.C. Water-soluble nanocrystals through dual-interaction ligands. Angew Chem Int Ed Engl 2008, 47(20):3730-3734.
96. Carion O., Mahler B., Pons T., Dubertret B. Synthesis, encapsulation, purification and coupling of single quantum dots in phospholipid micelles for their use in cellular and in vivo imaging. Nat Protoc 2007, 2(10):2383-2390.
97. Yang B.Y., Seelam S.R., Young I.K., Lee Y.S., Lee D.S., Chung J.K., et al. Preparation of a multimodal iron oxide nanoparticle conjugated with mannose, NOTA and PEG by encapsulation with specific amphiphiles. Paper presented at: Journal of labelled compounds & radiopharmaceuticals 2013.
98. Lee D.S. Preparation of multifunctional multimodal nanoparticles using specific amphiphiles: Click chemistry for nanoparticles. Annual Congress of Clinam (Abstr) 2013.
99. Lee D.S. In vivo application of Cu-64 labeled upconversion nanoparticles. Annual Congress of Clinam (Abstr) 2014.
100. Samanta A., Maiti K.K., Soh K.S., Liao X., Vendrell M., Dinish U.S., et al. Ultrasensitive near-infrared Raman reporters for SERS-based in vivo cancer detection. Angew Chem Int Ed Engl 2011, 50(27):6089-6092.
101. Kang H., Jeong S., Park Y., Yim J., Jun B.H., Kyeong S., et al. Near-infrared sers nanoprobes with plasmonic Au/Ag hollow-shell assemblies for in vivo multiplex detection. Adv Funct Mater 2013, 23(30):3719-3727.
102. Jun B.H., Hwang D.W., Jung H.S., Jang J., Kim H., Kang H., et al. Ultrasensitive, biocompatible, quantum-dot-embedded silica nanoparticles for bioimaging. Adv Funct Mater 2012, 22(9):1843-1849.
103. Tomalia D.A. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res 2009, 11(6):1251-1310.
104. Almeida J.P., Chen A.L., Foster A., Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond) 2011, 6(5):815-835.
105. Ntziachristos V., Tung C.H., Bremer C., Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002, 8(7):757-760.
106. Panagi Z., Beletsi A., Evangelatos G., Livaniou E., Ithakissios D.S., Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001, 221(1-2):143-152.
107. Jeong J.M., Hong M.K., Chang Y.S., Lee Y.S., Kim Y.J., Cheon G.J., et al. Preparation of a promising angiogenesis PET imaging agent: Ga-68-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008, 49(5):830-836.
108. Wang Y., Liu Y., Luehmann H., Xia X., Brown P., Jarreau C., et al. Evaluating the pharmacokinetics and in vivo cancer targeting capability of Au nanocages by positron emission tomography imaging. ACS Nano 2012, 6(7):5880-5888.
109. Sun X., Huang X., Yan X., Wang Y., Guo J., Jacobson O., et al. Chelator-free cu-integrated gold nanomaterials for positron emission tomography imaging guided photothermal cancer therapy. ACS Nano 2014, 8(8):8438-8446.
110. Liu Y., Sun Y., Cao C., Yang Y., Wu Y., Ju D., et al. Long-term biodistribution in vivo and toxicity of radioactive/magnetic hydroxyapatite nanorods. Biomaterials 2014, 35(10):3348-3355.
111. Choi H.S., Liu W., Misra P., Tanaka E., Zimmer J.P., Itty Ipe B., et al. Renal clearance of quantum dots. Nat Biotechnol 2007, 25(10):1165-1170.
112. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt 1):6387-6392.
113. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
114. Lehner R., Wang X., Marsch S., Hunziker P. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. Nanomedicine (Lond) 2013, 9(6):742-757.
115. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008, 60(15):1615-1626.
116. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007, 104(39):15549-15554.
117. Arora G., Shukla J., Ghosh S., Maulik S.K., Malhotra A., Bandopadhyaya G. PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose. PLoS One 2012, 7(3):e34019.
118. Karmali P.P., Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 2011, 8(3):343-357.
119. Cedervall T., Lynch I., Lindman S., Berggård T., Thulin E., Nilsson H., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci 2007, 104(7):2050-2055.
120. Monopoli M.P., Aberg C., Salvati A., Dawson K.A. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nano 2012, 7(12):779-786.
121. 99mTc-MSA) as a novel receptor binding agent for sentinel lymph node imaging. Nucl Med Commun 2004, 25(12):1211-1217.
122. Sun M., Sundaresan G., Jose P., Yang L., Hoffman D., Lamichhane N., et al. Highly stable intrinsically radiolabeled indium-111 quantum dots with multidentate zwitterionic surface coating: dual modality tool for biological imaging. J Mat Chem B 2014, 2:4456-4466.
123. Semmler-Behnke M., Kreyling W.G., Lipka J., Fertsch S., Wenk A., Takenaka S., et al. Biodistribution of 1.4- and 18-nm gold particles in rats. Small 2008, 4(12):2108-2111.
124. Lipka J., Semmler-Behnke M., Sperling R.A., Wenk A., Takenaka S., Schleh C., et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31(25):6574-6581.
125. Hirn S., Semmler-Behnke M., Schleh C., Wenk A., Lipka J., Schaffler M., et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 2011, 77(3):407-416.
126. Xie H., Wang Z.J., Bao A., Goins B., Phillips W.T. In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts. Int J Pharm 2010, 395(1-2):324-330.
127. Xie J., Chen K., Huang J., Lee S., Wang J., Gao J., et al. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010, 31(11):3016-3022.
128. Xiao Y., Hong H., Javadi A., Engle J.W., Xu W., Yang Y., et al. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 2012, 33(11):3071-3082.
129. Rangger C., Helbok A., Sosabowski J., Kremser C., Koehler G., Prassl R., et al. Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles. Int J Nanomedicine 2013, 8:4659-4671.
130. Souris J.S., Lee C.H., Cheng S.H., Chen C.T., Yang C.S., Ho J.A., et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 2010, 31(21):5564-5574.
131. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008, 3(5):703-717.
132. McNeil S.E. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1(3):264-271.
133. Ruggiero A., Villa C.H., Bander E., Rey D.A., Bergkvist M., Batt C.A., et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 2010, 107(27):12369-12374.
134. Yu T., Hubbard D., Ray A., Ghandehari H. In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release 2012, 163(1):46-54.
135. Cho W.S., Cho M., Jeong J., Choi M., Cho H.Y., Han B.S., et al. Acute toxicity and pharmacokinetics of 13nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 2009, 236(1):16-24.
136. Cho W.S., Cho M., Jeong J., Choi M., Han B.S., Shin H.S., et al. Size-dependent tissue kinetics of PEG-coated gold nanoparticles. Toxicol Appl Pharmacol 2010, 245(1):116-123.
137. Terentyuk G.S., Maslyakova G.N., Suleymanova L.V., Khlebtsov B.N., Kogan B.Y., Akchurin G.G., et al. Circulation and distribution of gold nanoparticles and induced alterations of tissue morphology at intravenous particle delivery. J Biophotonics 2009, 2(5):292-302.
138. Balasubramanian S.K., Jittiwat J., Manikandan J., Ong C.N., Yu L.E., Ong W.Y. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 2010, 31(8):2034-2042.
139. Gao H., Xiong J., Cheng T., Liu J., Chu L., Ma R., et al. In vivo biodistribution of mixed shell micelles with tunable hydrophilic/hydrophobic surface. Biomacromolecules 2013, 14(2):460-467.
140. Szebeni J., Bedocs P., Rozsnyay Z., Weiszhar Z., Urbanics R., Rosivall L., et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and Am Bisome. Nanomedicine (Lond) 2012, 8(2):176-184.
141. Beutler B.A. TLRs and innate immunity. Blood 2009, 113(7):1399-1407.
142. Seong S.-Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4(6):469-478.
143. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011, 11(3):221-230.
144. O'Neill L.A., Golenbock D., Bowie A.G. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 2013, 13(6):453-460.
145. Turabekova M., Rasulev B., Theodore M., Jackman J., Leszczynska D., Leszczynski J. Immunotoxicity of nanoparticles: a computational study suggests that CNTs and C60 fullerenes might be recognized as pathogens by Toll-like receptors. Nanoscale 2014, 6(7):3488-3495.
146. Ho C.C., Luo Y.H., Chuang T.H., Yang C.S., Ling Y.C., Lin P. Quantum dots induced monocyte chemotactic protein-1 expression via MyD88-dependent Toll-like receptor signaling pathways in macrophages. Toxicology 2013, 308:1-9.
147. Cejudo-Guillen M., Ramiro-Gutierrez M.L., Labrador-Garrido A., Diaz-Cuenca A., Pozo D. Nanoporous silica microparticle interaction with toll-like receptor agonists in macrophages. Acta Biomater 2012, 8(12):4295-4303.
148. Chen G.Y., Yang H.J., Lu C.H., Chao Y.C., Hwang S.M., Chen C.L., et al. Simultaneous induction of autophagy and toll-like receptor signaling pathways by graphene oxide. Biomaterials 2012, 33(27):6559-6569.
149. Yazdi A.S., Guarda G., Riteau N., Drexler S.K., Tardivel A., Couillin I., et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc Natl Acad Sci 2010, 107(45):19449-19454.
150. Sun B., Wang X., Ji Z., Li R., Xia T. NLRP3 inflammasome activation induced by engineered nanomaterials. Small 2013, 9(9-10):1595-1607.
151. Moyano D.F., Goldsmith M., Solfiell D.J., Landesman-Milo D., Miranda O.R., Peer D., et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc 2012, 134(9):3965-3967.
152. Thompson Elizabeth A., S B.C., Glista-Baker Ellen E., Shipkowski Kelly A., Taylor Alexia J., Bonner James C. Innate immune responses to nanoparticle exposure in the lung. J Environ Immunol Toxicol 2014, 2(1):46-52.
153. Mizrahy S., Raz S.R., Hasgaard M., Liu H., Soffer-Tsur N., Cohen K., et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release 2011, 156(2):231-238.
154. Mora-Solano C., Collier J.H. Engaging adaptive immunity with biomaterials. J Mater Chem B Mater Biol Med 2014, 2(17):2409-2421.
155. Smith M.J., Brown J.M., Zamboni W.C., Walker N.J. From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system. Toxicol Sci 2014, 138(2):249-255.
156. Schellekens H., Hennink W.E., Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013, 30(7):1729-1734.
157. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007, 122(3):349-355.
158. Rodriguez P.L., Harada T., Christian D.A., Pantano D.A., Tsai R.K., Discher D.E. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339(6122):971-975.
159. Oltra N.S., Nair P., Discher D.E. From stealthy polymersomes and filomicelles to "self" peptide-nanoparticles for cancer therapy. Annu Rev Chem Biomol Eng 2014, 5:281-299.
160. Adiseshaiah P.P., Hall J.B., McNeil S.E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2(1):99-112.
161. Johnston H.J., Semmler-Behnke M., Brown D.M., Kreyling W., Tran L., Stone V. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol 2010, 242(1):66-78.
162. Bergen J.M., von Recum H.A., Goodman T.T., Massey A.P., Pun S.H. Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 2006, 6(7):506-516.
163. Chen H., Wang L., Yeh J., Wu X., Cao Z., Wang Y.A., et al. Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. Biomaterials 2010, 31(20):5397-5407.
164. Pavot V., Rochereau N., Primard C., Genin C., Perouzel E., Lioux T., et al. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J Control Release 2013, 167(1):60-67.
165. Jenkins J.T., Halaney D.L., Sokolov K.V., Ma L.L., Shipley H.J., Mahajan S., et al. Excretion and toxicity of gold-iron nanoparticles. Nanomedicine 2013, 9(3):356-365.
166. Johnston H.J., Hutchison G., Christensen F.M., Peters S., Hankin S., Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit Rev Toxicol 2010, 40(4):328-346.
167. Ishida T., Harashima H., Kiwada H. Liposome clearance. Biosci Rep 2002, 22(2):197-224.
168. Ishida T., Ichihara M., Wang X., Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 2006, 115(3):243-250.
169. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006, 47(5):763-769.
170. Liu N., Li M., Li X., Meng X., Yang G., Zhao S., et al. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med 2009, 50(2):303-308.